Werewolf Therapeutics' WTX-330 Phase 1 shows unconfirmed partial response in melanoma; improved tolerability

Werewolf Therapeutics, Inc.

WTX-330 achieved 23-fold higher systemic IL-12 prodrug concentration vs rhIL-12 at 0.024 mg/kg; free IL-12 <1.6% of prodrug (cutoff June 12, 2024).
Unconfirmed partial response in metastatic melanoma patient who had progressed on adjuvant pembrolizumab; confirmatory scan pending.
Two MSS CRC patients achieved stable disease (one for 24 weeks); evidence of CD8+ T and NK cell activation in tumor biopsies.
No Grade 4/5 treatment-related AEs; mild-moderate toxicities (fever, chills, cytopenias) primarily first dose; MTD not established.
Expansion arms open at 0.024 mg/kg for ICI-resistant or ICI-naive patients; additional data expected Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.